408 related articles for article (PubMed ID: 22903949)
1. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM; Wilcox MH; Stein GE
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
[TBL] [Abstract][Full Text] [Related]
2. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
3. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Poon H; Chang MH; Fung HB
Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Jorgenson MR; DePestel DD; Carver PL
Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
[TBL] [Abstract][Full Text] [Related]
5. Ceftaroline fosamil: a new broad-spectrum cephalosporin.
Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii11-8. PubMed ID: 21482565
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Casapao AM; Steed ME; Levine DP; Rybak MJ
Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
[TBL] [Abstract][Full Text] [Related]
9. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
10. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Saravolatz LD; Stein GE; Johnson LB
Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
[TBL] [Abstract][Full Text] [Related]
13. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.
Korczowski B; Antadze T; Giorgobiani M; Stryjewski ME; Jandourek A; Smith A; O'Neal T; Bradley JS
Pediatr Infect Dis J; 2016 Aug; 35(8):e239-47. PubMed ID: 27164462
[TBL] [Abstract][Full Text] [Related]
14. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.
Merker A; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1741-50. PubMed ID: 25347329
[TBL] [Abstract][Full Text] [Related]
16. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
17. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
Garrison MW; Kawamura NM; Wen MM
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.
Steed ME; Rybak MJ
Pharmacotherapy; 2010 Apr; 30(4):375-89. PubMed ID: 20334458
[TBL] [Abstract][Full Text] [Related]
20. Ceftaroline fosamil: drug profile and clinical data.
Kanafani ZA
Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]